The company's bottom-line performance was underpinned by a 34 percent surge in foreign business, which reached Rs 1,665.2 crore. While European and rest-of-world markets posted substantial gains, domestic operations also maintained positive traction with an 11.1 percent increase. Total operational revenue climbed to Rs 2,820.47 crore, successfully outpacing an increase in total expenses to Rs 2,377.87 crore. For the full first half of the fiscal year, profit totaled Rs 617.56 crore, representing a 32.47 percent gain over the prior year.
Key points
International markets served as the primary growth engine, highlighted by a 36 percent in…: International markets served as the primary growth engine, highlighted by a 36 percent increase in Europe and a 41.1 percent rise across rest of the world regions.
The domestic business delivered steady growth by expanding 11.1 percent to generate Rs 1,…: The domestic business delivered steady growth by expanding 11.1 percent to generate Rs 1,155.3 crore in revenue.
Chief Executive Officer Satish Mehta expects the strong business momentum established in…: Chief Executive Officer Satish Mehta expects the strong business momentum established in the first half to continue throughout the remainder of the fiscal year.
Sources checked by our analysis pipeline: 1
The pharma company had posted a profit of Rs 251.37 crore in the year-ago period, it said in a regulatory filing.
Its revenue from operations rose to Rs 2,820.47 crore during the September quarter, up from Rs 2,269.82 crore a year earlier.
Its total expenses were higher at Rs 2,377.87 crore during the quarter under review, up from Rs 1,931.52 crore a year ago, as per the filing.
The company recorded a strong 34 per cent growth in international business to Rs 1,665.2 crore during the quarter while its domestic business rose 11.1 per cent to Rs 1,155.3 crore, according to a statement.
In its international business, Europe grew 36 per cent, Canada was up 24 per cent, while in the rest of the world markets, it showed a growth of 41.1 per cent, as per the statement.
During the April-September period (H1), the company posted a profit of Rs 617.56 crore, 32.47 per cent higher than Rs 466.16 crore in the year-ago period.
Emcure Pharmaceuticals Chairman, Managing Director and CEO Satish Mehta said, "Q2 was another strong quarter for…
The Leeds-based grocer is handing executive leadership to David Potts to drive a multi-year turnaround after severe IT upgrade disruptions recently undermined product availability and profits. Outgoing leader Allan Leighton will shift to non-executive chairman as planned, following a two-year stabilization effort. The incoming leadership aims to maintain low prices and capitalize on the business's recent return to quarterly sales growth.
The structural overhaul across the firm's alternates, retail, and wealth verticals aims to strengthen institutional capabilities following a string of senior departures. The executive reshuffle arrives alongside robust quarterly financial momentum, which has helped spur immediate investor optimism in the public markets.
Technology giants are restructuring their operational footprints to fund massive infrastructure bets without inflating long-term payrolls. By targeting more than a quarter of its workforce with voluntary exit proposals, the company creates financial flexibility as it reallocates resources. This substantial staff reduction immediately preceded a major surge in capital deployed toward cutting-edge artificial intelligence projects.